DPP4 and Myocardial fibrosis: Additionally, saxagliptin-mediated dipeptidyl peptidase-4 (DPP-4) inhibition elevates circulating stromal cell-derived factor-1α (SDF-1α), potentially exacerbating myocardial fibrosis and inflammatory responses (79).